Funding will support completion of IND-enabling activities and planned year-end IND submission

资金将用于支持完成新药临床试验申请（IND）的准备工作，并按计划于年底提交IND申请。

for TAVST01

针对 TAVST01

image credit- shutterstock

图片来源：Shutterstock

Tikva Allocell, a Singapore-based biotechnology startup developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumours, has announced the closing of an $8 million Series A financing led by Kantharos Capital.

总部位于新加坡的生物科技初创公司Tikva Allocell专注于为患有实体瘤的成人和儿科患者开发工程化同种异体（供体来源）细胞疗法，该公司宣布完成由Kantharos Capital领投的800万美元A轮融资。

Proceeds will fund IND-enabling activities and a planned year-end 2026 Investigational New Drug (IND) submission for TAVST01, Tikva’s lead candidate for B7-H3-positive solid tumours. Subject to regulatory clearance, the company plans to initiate a Phase 1 clinical trial in patients with advanced B7-H3-positive cancer at sites in Singapore and the United States..

所得款项将用于支持TAVST01的IND申报准备工作，并计划于2026年底提交新药临床试验申请（IND）。TAVST01是Tikva公司针对B7-H3阳性实体瘤的主要候选药物。在获得监管机构批准后，公司计划在新加坡和美国的临床研究中心启动一项针对晚期B7-H3阳性癌症患者的I期临床试验。

TAVST01 targets B7-H3, a protein expressed across a broad range of difficult-to-treat solid tumors, including lung, breast, prostate, pancreatic, and pediatric cancers. Unlike conventional donor-derived cell therapies, which a patient’s immune system often clears before they can work, TAVST01 is built from Epstein-Barr virus (EBV)-specific T cells - immune cells the body naturally sustains - and is engineered to resist that rejection, with preclinical potential both to kill tumor cells directly and to remodel the immunosuppressive microenvironment that has limited cell therapies in solid tumours..

TAVST01 靶向 B7-H3，这是一种在多种难治性实体瘤（包括肺癌、乳腺癌、前列腺癌、胰腺癌和儿童癌症）中广泛表达的蛋白质。与传统的供者来源细胞疗法不同（患者的免疫系统往往在其发挥作用前就将其清除），TAVST01 由爱泼斯坦-巴尔病毒（EBV）特异性 T 细胞构建而成——这类免疫细胞可在体内自然持续存在——并经过工程化改造以抵抗免疫排斥。临床前研究显示，TAVST01 既具有直接杀伤肿瘤细胞的潜力，又能重塑限制实体瘤细胞疗法疗效的免疫抑制微环境。

Tikva’s therapies are built on the ALLO SerpinB9 EBVST platform — an allogeneic, virus-specific T-cell technology licensed exclusively from Baylor College of Medicine and further enhanced through Tikva’s proprietary protein-engineering strategies. These cells are equipped with a B7-H3–targeting receptor and an optimised form of SerpinB9, a natural inhibitor of granzyme B, the enzyme immune cells use to kill their targets..

Tikva 的疗法基于 ALLO SerpinB9 EBVST 平台——这是一种同种异体、病毒特异性 T 细胞技术，独家授权自贝勒医学院，并通过 Tikva 专有的蛋白质工程策略进一步增强。这些细胞配备了靶向 B7-H3 的受体以及优化形式的 SerpinB9，后者是颗粒酶 B 的天然抑制剂，而颗粒酶 B 是免疫细胞用于杀伤靶细胞的酶。